Clinical trials: Healthy Female Adult Volunteers
Healthy
Study on Adhesion Properties of Three Different Adhesives
This clinical investigation is a single centre, double blinded, case control study in healthy adult females. This study will be conducted in private rooms at Gentofte Hospital (Hjerte-medicinsk Forskning, post 835, Kildegårdsvej…
- Trial name
- NCT04125797
- Testing
- Application of adhesive
- Where
- Denmark
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Ambu A/S
Impaired Liver Function
Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults
This study will evaluate the safety and pharmacokinetics of two doses of orally administered Proellex® in female patients with impaired hepatic function and healthy volunteers with normal hepatic function.
- Trial name
- NCT00741273
- Testing
- Proellex
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Male & Female Healthy Volunteers
Bioavailability Study of COQUN ORAL FORMULATION
The goal of the study is to evaluate the best dosage for COQUN ORAL FORMULATION in order to reach a level of plasma concentration which might assure its antioxidant effect if taken on a regular basis.
- Trial name
- NCT03819491
- Testing
- COQUN ORAL FORMULATION
- Where
- Romania
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- VISUfarma SpA
Severe Renal Impairment
Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers
This is a Phase 4, multicenter, open label, 1 period study. A total of 16 subjects are planned (8 subjects in Group A and 8 subjects in Group B): The 2 groups will be comparable in terms of age, gender, and body mass index (BMI)…
- Trial name
- NCT01043094
- Testing
- Pitavastatin 4mg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kowa Research Institute, Inc.
Healthy Volunteers
A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact.
- Trial name
- NCT04273217
- Testing
- AV-1
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- AbViro LLC
Healthy Volunteer
Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
Phase 1 single IV dose study to evaluate safety and tolerability of MEDI4920
- Trial name
- NCT02151110
- Testing
- MEDI4920 3 mg, MEDI4920 10 mg, MEDI4920 30 mg
- Where
- United Kingdom
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy Volunteers
A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
This is a first-in-human (FIH), randomized, placebo-controlled, double-blind, single ascending dose (SAD) study to assess the safety and tolerability of VIS954, a monoclonal antibody, in healthy adult male and female participants.
- Trial name
- NCT06212804
- Testing
- VIS954
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Kidney Failure, Chronic
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).
- Trial name
- NCT00875017
- Testing
- Lanthanum Carbonate, Sevelamer
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Shire
Healthy Volunteers
A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women
The purpose of this trial is to assess the potential for cytochrome P450 (CYP)-mediated drug-drug interactions (DDIs) with OPC-167832.
- Trial name
- NCT07542847
- Testing
- OPC-167832, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Insomnia
VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia
The purpose of this study is to determine the safety and efficacy of VEC-162 compared to placebo to improve sleep parameters in a model of insomnia.
- Trial name
- NCT00291187
- Testing
- 20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162
- Where
- 19 sites in United States
- Volunteers
- 411 people, healthy volunteers welcome
- Sponsor
- Vanda Pharmaceuticals
Healthy
Drug - Drug Interaction Study of Quinine Sulfate and Ciprofloxacin
Ciprofloxacin is moderate inhibitor of cytochrome P450 1A2 (CYP1A2), one of the enzymes responsible for the metabolism of quinine.
- Trial name
- NCT00785980
- Testing
- Quinine Sulfate Capsules 324 mg, Ciprofloxacin 500 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Ascites Hepatic
A Study of OsrHSA in Adult Healthy Male and Female Volunteers
A Phase 1 randomized, double blinded, placebo-controlled single dose escalation study of OsrHSA in adult healthy male and female volunteers
- Trial name
- NCT04384523
- Testing
- OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Healthgen Biotechnology Corp.
End Stage Renal Disease
Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
This is a Phase 1, open-label, three-period sequential dosing study being conducted to determine the pharmacokinetics of Triferic iron administered intravenously (IV) to healthy adults.
- Trial name
- RMFPC-12 (NCT02636049)
- Testing
- Triferic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rockwell Medical Technologies, Inc.